Human T-PA (residues 1-3 And 176-527)

Human T-PA (residues 1-3 And 176-527) Uses, Dosage, Side Effects, Food Interaction and all others data.

Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).

Human T-PA (residues 1-3 And 176-527) cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.

Human T-PA (residues 1-3 And 176-527)
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Human T-PA (residues 1-3 And 176-527)
Availability	Prescription only
Generic	Reteplase
Reteplase Other Names	Human t-PA (residues 1-3 and 176-527), Reteplasa, Reteplase, Reteplase, recombinant, Reteplase,recombinant
Related Drugs	aspirin, lisinopril, metoprolol, propranolol, Plavix, Brilinta
Type
Formula	C₁₇₃₆H₂₆₇₁N₄₉₉O₅₂₂S₂₂
Weight	39589.6 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Human T-PA (residues 1-3 And 176-527) is a purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.

For lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction.

Human T-PA (residues 1-3 And 176-527) is also used to associated treatment for these conditions: Acute Myocardial Infarction (AMI), Cardiovascular Mortality, Congestive Heart Failure (CHF)

How Human T-PA (residues 1-3 And 176-527) works

Human T-PA (residues 1-3 And 176-527) binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.

Food Interaction

Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Human T-PA (residues 1-3 And 176-527) Hypertension interaction

[Major] The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma

Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.

Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.

Measures of fibrinolytic activity and